Enzo Biochem Inc. (ENZ) Scheduled to Post Quarterly Earnings on Friday
Enzo Biochem Inc. (NYSE:ENZ) is scheduled to issue its Q416 quarterly earnings data on Friday, October 14th.
Shares of Enzo Biochem Inc. (NYSE:ENZ) opened at 5.09 on Thursday. The company has a 50 day moving average of $5.36 and a 200-day moving average of $5.69. Enzo Biochem Inc. has a 12-month low of $3.48 and a 12-month high of $7.00. The firm has a market cap of $235.48 million, a price-to-earnings ratio of 13.32 and a beta of 1.50.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Spark Investment Management LLC boosted its position in Enzo Biochem by 113.3% in the second quarter. Spark Investment Management LLC now owns 99,200 shares of the company’s stock valued at $592,000 after buying an additional 52,700 shares during the last quarter. Rhumbline Advisers bought a new position in Enzo Biochem during the second quarter valued at $233,000. Perceptive Advisors LLC bought a new position in Enzo Biochem during the second quarter valued at $401,000. Teachers Advisors Inc. bought a new position in Enzo Biochem during the second quarter valued at $373,000. Finally, American International Group Inc. boosted its position in Enzo Biochem by 2,184.6% in the second quarter. American International Group Inc. now owns 22,846 shares of the company’s stock valued at $136,000 after buying an additional 21,846 shares during the last quarter. 53.29% of the stock is owned by hedge funds and other institutional investors.
Separately, Zacks Investment Research raised shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a report on Thursday, June 16th.
About Enzo Biochem
Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.
Receive News & Stock Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related stocks with our FREE daily email newsletter.